Evergreen Youth Secrets
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
No Result
View All Result
Evergreen Youth Secrets
No Result
View All Result
Home Health Care

PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC

by
January 14, 2025
in Health Care
0
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through vertical integration, industry dominance and marking up the prices of specialty drugs.

The report specifically looked at the business practices of the Caremark Rx, Express Scripts and OptumRx, which are in turn owned by CVS Health, Cigna and UnitedHealth Group, respectively. These companies are considered the “Big 3” in the PBM industry, controlling roughly 60 percent of the market.

“The FTC staff’s second interim report finds that the three major pharmacy benefit managers hiked costs for a wide range of lifesaving drugs, including medications to treat heart disease and cancer,” FTC Chair Lina Khan said in a statement.

Khan said during an FTC open commission meeting to discuss the findings on Tuesday that the five-person commission had voted unanimously in favor of issuing the report.

According to the report, the “Big 3” PBMs marked up the prices of many specialty generic drugs by hundreds or thousands of percent.

Significantly marking up the prices 51 such drugs helped PBM-affiliated pharmacies generate $7.3 billion in revenue between 2017 and 2022. The commission noted these prices were in excess of the National Average Drug Acquisition Cost (NADAC) for these drugs.

As is noted in the report, there is no set definition for what specialty drugs are. The Office of Inspector General for the Department of Health and Human Services has previously said a product can be considered a specialty drug because it may be “expensive; be difficult to handle, monitor or administer; or treat rare, complex or chronic conditions.”

The FTC found that 22 percent of specialty drugs dispensed by PBM-affiliated pharmacies were marked up by more than 1,000 percent while 41 percent were marked up between 100 and 1,000 percent. Among those drugs marked up by more than 1,000 percent, half of them were marked up by more than 2,000 percent.

In 2023, the top three PBMs dispensed the majority of specialty drugs in the U.S. at 68 percent, a double-digit hike from when it dispensed 54 percent of specialty drugs in 2016.

“Specialty generic drugs represented a growing profit center for the Big 3 PBMs and their affiliated pharmacies during our study period from 2017 through part of 2022,” the report found.

“Given the combination of high reimbursement rates and large dispensing volumes, the Big 3 PBMs’ affiliated pharmacies generated significant and growing levels of revenue in excess of estimated acquisition cost (NADAC) on the most highly marked up specialty generic drugs during the study period, while the Big 3 PBMs also appeared to take in significant income from spread pricing on these drugs, in aggregate,” the report continued, while noting plans sponsors and patients paid “substantially” more in that same time frame.

Antitrust attorney Austin Ownbey spoke on behalf of the Pharmaceutical Care Management Association (PCMA), a trade organization that represents PBMs, during the open commission meeting Tuesday.

“PCMA has significant concerns that a second interim report regarding specialty drugs is unlikely to be anything other than a piece of advocacy without substantiating evidence,” said Ownbey. “Specialty drugs offer the most effective and, in some cases, the only treatment for illness and conditions that historically had few treatment options, including multiple sclerosis, cystic fibrosis, cancer and autoimmune disorders.”

PBM practices have incurred significant bipartisan scrutiny in Congress. Sens. Elizabeth Warren (D-Mass.) and Josh Hawley (R-Mo.) as well as Reps. Jake Auchincloss (D-Mass.) and Diana Harshbarger (R-Tenn.) called on the FTC to issue its second interim staff report. The lawmakers said they expected the report would inform future legislation on PBMs.

Previous Post

‘Forever chemicals’ in sludge used to fertilize farms can pose a health risk to people, EPA says

Next Post

Federal judge blocks FDA from enforcing graphic cigarette label rule

Next Post
Federal judge blocks FDA from enforcing graphic cigarette label rule

Federal judge blocks FDA from enforcing graphic cigarette label rule

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

    Popular News

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    June 27, 2025
    FDA expanding COVID vaccine warnings over rare heart side effect

    FDA expanding COVID vaccine warnings over rare heart side effect

    June 27, 2025
    Supreme Court upholds HHS authority over ObamaCare preventative care task force

    Supreme Court upholds HHS authority over ObamaCare preventative care task force

    June 27, 2025

    Trending

    Hillary Clinton shares condolences after Biden cancer diagnosis

    Hillary Clinton shares condolences after Biden cancer diagnosis

    May 18, 2025
    Comer says GOP seeking evidence of Fauci’s ‘criminal wrongdoing’

    Comer says GOP seeking evidence of Fauci’s ‘criminal wrongdoing’

    June 4, 2024
    Sunday shows preview: All eyes on looming Trump-Biden debate

    Sunday shows preview: All eyes on looming Trump-Biden debate

    June 22, 2024
    Trump administration directs federal health agencies to pause communications

    Trump administration directs federal health agencies to pause communications

    January 22, 2025

    Recent News

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    June 27, 2025
    FDA expanding COVID vaccine warnings over rare heart side effect

    FDA expanding COVID vaccine warnings over rare heart side effect

    June 27, 2025

    Popular News

    • New Hampshire lawmakers give final approval to gender-affirming care ban 
    • FDA expanding COVID vaccine warnings over rare heart side effect

    About Evergreen Youth Secrets

    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.

    No Result
    View All Result
    • Health News
    • Health Care
    • Staying Healthy
    • Beauty Advices

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.